S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000967776.81028.41 |
| _version_ | 1797279790405779456 |
|---|---|
| author | Huilai Zhang Jingwei Yu He LI Wenbin Qian Xibin Xiao Qingqing Cai Yao Liu Yu Zhang Liling Zhang Ling Qin Hui Zhou Xiaoyi Tang Yingmei Guo Hui Zhou Ting Niu |
| author_facet | Huilai Zhang Jingwei Yu He LI Wenbin Qian Xibin Xiao Qingqing Cai Yao Liu Yu Zhang Liling Zhang Ling Qin Hui Zhou Xiaoyi Tang Yingmei Guo Hui Zhou Ting Niu |
| author_sort | Huilai Zhang |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:32:08Z |
| format | Article |
| id | doaj.art-003a6f7b7c7f4d59ae6b6daae8e5fcc9 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:32:08Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-003a6f7b7c7f4d59ae6b6daae8e5fcc92024-03-03T10:10:09ZengWileyHemaSphere2572-92412023-08-017e810284110.1097/01.HS9.0000967776.81028.41202308003-00118S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDYHuilai Zhang0Jingwei Yu1He LI2Wenbin Qian3Xibin Xiao4Qingqing Cai5Yao Liu6Yu Zhang7Liling Zhang8Ling Qin9Hui Zhou10Xiaoyi Tang11Yingmei Guo12Hui Zhou13Ting Niu141 Tianjin Medical University Cancer Institute & Hospital, Tianjin, China1 Tianjin Medical University Cancer Institute & Hospital, Tianjin, China2 West China Hospital of Sichuan University, Chengdu, China3 The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China3 The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China4 Sun Yat-sen University Cancer Center, Guangzhou, China5 Chongqing University Cancer Hospital, Chongqing, China6 Union Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan, China6 Union Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan, China7 The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China8 Hunan Cancer Hospital, Changsha, China10 Innovent Biologics Inc., Suzhou, China10 Innovent Biologics Inc., Suzhou, China10 Innovent Biologics Inc., Suzhou, China2 West China Hospital of Sichuan University, Chengdu, Chinahttp://journals.lww.com/10.1097/01.HS9.0000967776.81028.41 |
| spellingShingle | Huilai Zhang Jingwei Yu He LI Wenbin Qian Xibin Xiao Qingqing Cai Yao Liu Yu Zhang Liling Zhang Ling Qin Hui Zhou Xiaoyi Tang Yingmei Guo Hui Zhou Ting Niu S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY HemaSphere |
| title | S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY |
| title_full | S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY |
| title_fullStr | S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY |
| title_full_unstemmed | S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY |
| title_short | S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY |
| title_sort | s216 cd47 pd l1 bispecific antibody ibi322 in anti pd 1 or pd l1 treatment resistant classical hodgkin lymphoma a phase i study |
| url | http://journals.lww.com/10.1097/01.HS9.0000967776.81028.41 |
| work_keys_str_mv | AT huilaizhang s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT jingweiyu s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT heli s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT wenbinqian s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT xibinxiao s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT qingqingcai s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT yaoliu s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT yuzhang s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT lilingzhang s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT lingqin s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT huizhou s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT xiaoyitang s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT yingmeiguo s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT huizhou s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy AT tingniu s216cd47pdl1bispecificantibodyibi322inantipd1orpdl1treatmentresistantclassicalhodgkinlymphomaaphaseistudy |